Healthcare / Telehealth & Consumer HealthTechnical Analysis Guide

HIMS Stock Analysis

Hims & Hers Health, Inc.

💡 Quick Answer

Across 4 APEX technical signals, HIMS is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.

HIMS has ATR of 8-13% and is the highest-profile telehealth platform with the most direct exposure to the GLP-1 weight loss drug market. Post-earnings moves of 15-22% are typical.

Subscriber Growth: Total member base expansionGLP-1 Transition: Post-compounding semaglutideRSI Behavior: High-volatility health 28-75 range

Hims & Hers is a telehealth platform offering prescription medications, OTC products, and personalized treatment plans for hair loss (finasteride, minoxidil), erectile dysfunction (sildenafil), mental health, skincare, weight management (GLP-1 medications), and women's health (contraception, menopause). Its direct-to-consumer model bypasses traditional pharmacy networks. Patients consult providers through the Hims app, prescriptions are written and filled by Hims-affiliated pharmacies, and products are shipped directly to the customer.

LIVE CHART·HIMS. DailyPowered by TradingView

📊 Open HIMS on TradingView ↗Affiliate link

Get live HIMS signal analysis

APEX runs 8 signals on HIMS in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze HIMS Now →

Why Do Traders Watch HIMS?

HIMS has ATR of 8-13% and is the highest-profile telehealth platform with the most direct exposure to the GLP-1 weight loss drug market. Post-earnings moves of 15-22% are typical. HIMS was a major beneficiary of FDA-authorized compounding of semaglutide (Ozempic/Wegovy) during the shortage, generating significant GLP-1 revenue. When FDA ended the shortage designation in 2025, a major HIMS revenue tailwind ended. The transition to a new sustainable business model is the current investment narrative.

Is HIMS a Buy Right Now? Current Signal Readings

💰Subscriber GrowthTotal member base expansion

Hims' quarterly subscriber count. The total number of paying members across all treatment categories. Is the primary business volume metric. Subscriber growth above 35% year-over-year signals strong top-of-funnel acquisition and retention across hair, ED, mental health, and weight management categories. LTV/CAC (lifetime value to customer acquisition cost) above 3× is the efficiency threshold management targets.

📊GLP-1 TransitionPost-compounding semaglutide

After the FDA shortage designation ended in 2025, Hims shifted from compounded semaglutide to a diversified weight loss portfolio (branded GLP-1 dispensing, oral GLP-1 alternatives, personalized nutrition programs). The revenue sustainability and margin profile of the post-GLP-1 compounding business is the central thesis question. Track weight management subscriber retention above 60% as the key health indicator.

📊RSI BehaviorHigh-volatility health 28-75 range

HIMS's RSI swings dramatically with FDA regulatory news and GLP-1 market developments. RSI below 32 following GLP-1 headwind announcements. When core hair and ED subscription businesses remain growing above 25%. Have been contrarian entries for investors who separate the GLP-1 catalyst from the core subscription health business.

💲EBITDA ProfitabilityPath to sustainable margins

Hims achieved adjusted EBITDA profitability earlier than consensus expected, demonstrating that the DTC telehealth subscription model has structurally positive unit economics. Maintaining EBITDA margins above 10% through the GLP-1 transition while subscriber growth stays above 25% is the combination that validates the durable business model thesis and supports a growth-oriented stock multiple.

📋 HIMS Key Stats for Traders

⚡ATR (14-day)8-13% of price

📦Avg daily volume~15-25 million shares

🎯Key metricSubscriber growth + weight mgmt retention

📅Post-earnings move15-22% typical

🔗 Related Stocks

TDOCAMWLDOCSNVO

Run a live HIMS analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze HIMS Free →

📊 Advanced charting for HIMS on TradingView ↗

💬 Frequently Asked Questions. HIMS

QIs HIMS a good stock to buy right now?

AWhether HIMS is a buy depends on its current technical positioning. HIMS has ATR of 8-13% and is the highest-profile telehealth platform with the most direct exposure to the GLP-1 weight loss drug market. Post-earnings moves of 15-22% are typical. HIMS was a major beneficiary of FDA-authorized compounding of semaglutide (Ozempic/Wegovy) during the shortage, generating significant GLP-1 revenue. When FDA ended the shortage designation in 2025, a major HIMS revenue tailwind ended. The transition to a new sustainable business model is the current investment narrative. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for HIMS?

AThe four key signals for HIMS are: Subscriber Growth (Total member base expansion). Hims' quarterly subscriber count. The total number of paying members across all treatment categories. Is the primary business volume metric. Subscriber growth above 35% year-over-year signals strong top-of-funnel acquisition and retention across hair, ED, mental health, and weight management categories. LTV/CAC (lifetime value to customer acquisition cost) above 3× is the efficiency threshold management targets.. GLP-1 Transition (Post-compounding semaglutide). After the FDA shortage designation ended in 2025, Hims shifted from compounded semaglutide to a diversified weight loss portfolio (branded GLP-1 dispensing, oral GLP-1 alternatives, personalized nutrition programs). The revenue sustainability and margin profile of the post-GLP-1 compounding business is the central thesis question. Track weight management subscriber retention above 60% as the key health indicator.. RSI Behavior (High-volatility health 28-75 range). HIMS's RSI swings dramatically with FDA regulatory news and GLP-1 market developments. RSI below 32 following GLP-1 headwind announcements. When core hair and ED subscription businesses remain growing above 25%. Have been contrarian entries for investors who separate the GLP-1 catalyst from the core subscription health business.. EBITDA Profitability (Path to sustainable margins). Hims achieved adjusted EBITDA profitability earlier than consensus expected, demonstrating that the DTC telehealth subscription model has structurally positive unit economics. Maintaining EBITDA margins above 10% through the GLP-1 transition while subscriber growth stays above 25% is the combination that validates the durable business model thesis and supports a growth-oriented stock multiple.

QWhat is HIMS's RSI telling traders right now?

AHIMS's RSI swings dramatically with FDA regulatory news and GLP-1 market developments. RSI below 32 following GLP-1 headwind announcements. When core hair and ED subscription businesses remain growing above 25%. Have been contrarian entries for investors who separate the GLP-1 catalyst from the core subscription health business. APEX scores HIMS's RSI as part of its 8-factor composite signal. Updated daily.

QHow does HIMS behave technically compared to other Healthcare / Telehealth & Consumer Health stocks?

AHIMS is in the Healthcare / Telehealth & Consumer Health sector. Hims & Hers is a telehealth platform offering prescription medications, OTC products, and personalized treatment plans for hair loss (finasteride, minoxidil), erectile dysfunction (sildenafil), mental health, skincare, weight management (GLP-1 medications), and women's health (contraception, menopause). Its direct-to-consumer model bypasses traditional pharmacy networks. Patients consult providers through the Hims app, prescriptions are written and filled by Hims-affiliated pharmacies, and products are shipped directly to the customer. Key stats: ATR (14-day): 8-13% of price, Avg daily volume: ~15-25 million shares, Key metric: Subscriber growth + weight mgmt retention, Post-earnings move: 15-22% typical.

QWhat MACD signals work best for HIMS?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks HIMS's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−